Gilead Sciences, Inc.GILDNASDAQ
Loading
EBITDA Margin Over TimeStable
Percentile Rank29
3Y CAGR+4.2%
5Y CAGR+17.0%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
+4.2%/yr
vs -8.6%/yr prior
5Y CAGR
+17.0%/yr
Recent deceleration
Acceleration
+12.9pp
Accelerating
Percentile
P29
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive growthStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 36.75% | +138.3% |
| 2024 | 15.42% | -60.2% |
| 2023 | 38.71% | +19.3% |
| 2022 | 32.45% | -21.8% |
| 2021 | 41.49% | +147.8% |
| 2020 | 16.74% | -50.3% |
| 2019 | 33.67% | -27.7% |
| 2018 | 46.57% | -23.7% |
| 2017 | 61.03% | -3.5% |
| 2016 | 63.24% | - |